Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
44.75    2.25 (5.29%)
Bid:
44.50
Ask:
45.00
Spread: 0.50 (1.124%)
Market Cap: £85.86m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Corporate and Production Update

14 Jul 2017 07:00

RNS Number : 0327L
Iofina PLC
14 July 2017
 

 

14 July 2017

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

H1 2017 Market Update

 

Exceeds anticipated iodine production output

 

Iofina, specialists in the exploration and production of iodine and halogen based specialty chemical derivatives, today provides an update to the market regarding its activities in the first half ('H1' or the 'Period') of 2017.

 

Iofina produced 235.5 metric tonnes ('MT') of crystalline iodine in H1 from its Oklahoma based IOsorb® plants, exceeding the Company's expected output of 215-230 MT. During the Period, IOsorb® plant IO#3 was shut-in due to lack of brine supply and the Company continues to make positive strides in its intention to move this facility to a superior location in our core area. At present, final details are being resolved and we will update the market once all the specifics to allow for the relocation are complete.

 

Iofina Chemical performed well in the Period, with demand for both iodine and non-iodine based halogen products remaining robust. The Company has increased Research and Development activity in the Period in order to meet new market demands and inquiries for specialty chemical products.

 

Looking forward, Iofina expects to produce between 225-240 MT of crystalline iodine in H2 of 2017 from the four currently operating IOsorb® plants.

 

Iodine prices were relatively stable over the last two months but remain below historical levels. Whilst not certain, the Board believes there is presently a greater probability for iodine prices to increase in both the near and long term, based on current supply and demand indications for iodine.

 

Commenting, President and CEO Dr. Tom Becker, stated: 

''Despite having to adjust our output forecast following the IO#3 shut-in, the Board is pleased that we were able to exceed our production targets in H1, which is testament to the improved processes and efficiencies. Iofina continues to make positive progress towards the reutilisation of the Company's IO#3 assets. This is critical in order for Iofina to meet its goals of reducing costs and expanding production. We look forward to updating the market once all details are finalised." 

 

Enquiries:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Emily Morris

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7544 275 882

 About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb® technology. Iofina has operations in the United States, specifically in Montana, Kentucky and Oklahoma. It has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end-products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDUOASRBNABAAR
Date   Source Headline
5th Jun 20267:00 amRNSAgreement Signed for Additional Brine Water Supply
5th May 20267:00 amRNSNotice of AGM
30th Apr 20264:45 pmRNSHolding(s) in Company
30th Apr 202611:30 amRNSHolding(s) in Company
30th Apr 20267:00 amRNSFinal Results
16th Apr 20261:40 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSQ1 2026 Corporate Update
20th Mar 202612:25 pmRNSHolding(s) in Company
13th Jan 20267:00 amRNSQ4 2025 Corporate Update
6th Jan 20267:00 amRNSHolding(s) in Company
12th Dec 20257:00 amRNSDirectorate change
5th Dec 20257:00 amRNSAgreement with Western Midstream
12th Nov 20258:15 amRNSHolding(s) in Company
16th Oct 20257:00 amRNSQ3 2025 Update
3rd Oct 20253:32 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSBusiness Update
17th Jul 20257:00 amRNSH1 2025 Update
9th Jul 20257:00 amRNSCapital Reduction
9th Jun 20255:00 pmRNSResult of AGM
14th May 20257:00 amRNSNotice of AGM and Proposed Capital Reduction
12th May 20257:00 amRNS-RInvestor Presentation
12th May 20257:00 amRNSFinal Results
25th Apr 20253:45 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 2025 Update
23rd Jan 20257:00 amRNSQ4 2024 Update
18th Dec 20244:45 pmRNSHolding(s) in Company
21st Oct 20247:00 amRNSHolding(s) in Company
18th Oct 20247:00 amRNSQ3 2024 Update
27th Sep 20247:00 amRNSIO#11 Update
20th Sep 20247:00 amRNSInterim Results
13th Sep 20247:00 amRNSIO#10 Iodine Plant Commissioned
16th Jul 20247:00 amRNSH1 Update
27th Jun 202411:04 amRNSHolding(s) in Company
25th Jun 20247:00 amRNSHolding(s) in Company
13th Jun 20241:00 pmRNSResult of AGM
29th May 20244:50 pmRNSLaunch of new website
15th May 20247:00 amRNSNotice of AGM and Resignation of Director
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.